Novel Cell Therapy (Kyowa Kirin Collab.)
Undisclosed Diseases with High Unmet Need
ResearchActive
Key Facts
Indication
Undisclosed Diseases with High Unmet Need
Phase
Research
Status
Active
Company
About Cimeio Therapeutics
Cimeio Therapeutics is developing a groundbreaking platform that pairs gene-edited, 'shielded' cells with potent immunotherapies to create curative treatments for hematologic diseases. Its core innovation involves editing cell surface proteins to maintain function while making them invisible to paired therapies like antibodies, ADCs, and CAR-T cells, allowing for targeted conditioning and disease eradication. The company has validated its approach with a high-profile Nature publication and secured a significant partnership with Kyowa Kirin valued at up to $300 million, positioning it as a leader in next-generation cell and gene therapies.
View full company profile